ABBV AbbVie Inc

By Colin Kellaher

AbbVie Inc. on Tuesday said the U.S. Food and Drug Administration accepted its new drug application for atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine.

The North Chicago, Ill., biopharmaceutical company said it expects a decision from the agency late in the third quarter.

AbbVie said atogepant, if approved, would be the first and only oral calcitonin gene-related peptide receptor antagonist specifically developed for the preventive treatment of migraine.

AbbVie already markets Botox as a preventive treatment for chronic migraine and Ubrelvy as an acute treatment for adults with migraine.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 30, 2021 08:35 ET (12:35 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.